SCHEMBL4736503

SCHEMBL4736503

Nc1onc2c(CN3CCOCC3)ccc(-c3ccc(NC(=O)Nc4cccc(C(F)(F)F)c4)cc3)c12

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IKBKE Q14164 1/20 0.65
KDR P35968 14/20 0.56
FLT3 P36888 12/20 0.56
KIT P10721 10/20 0.56
PDGFRB P09619 3/20 0.55
FLT1 P17948 6/20 0.54
CSF1R P07333 5/20 0.54
TEK Q02763 2/20 0.54
THRB P10828 1/20 0.53
LCK P06239 4/20 0.49
LYN P07948 4/20 0.49
FLT4 P35916 4/20 0.49
BLK P51451 4/20 0.49
FYN P06241 3/20 0.49
SRC P12931 2/20 0.49
ABL1 P00519 1/20 0.49
ROCK2 O75116 3/20 0.49
RET P07949 3/20 0.49
RPS6KB1 P23443 3/20 0.49
EPHA2 P29317 3/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL420675 0.89 IKBKE (0.81) IKBKEKDRFLT3KITPDGFRB
SCHEMBL1381921 0.89 IKBKE (0.82) IKBKEKDRFLT3KITPDGFRB
SCHEMBL1383488 0.88 KDR (0.58) IKBKEKDRFLT3KITPDGFRB
SCHEMBL4739851 0.88 KDR (0.58) IKBKEKDRFLT3KITPDGFRB
SCHEMBL4735824 0.88 KDR (0.72) IKBKEKDRFLT3KITPDGFRB
SCHEMBL4740259 0.86 KDR (0.59) IKBKEKDRFLT3KITPDGFRB
SCHEMBL1378823 0.85 KDR (0.56) IKBKEKDRFLT3KITPDGFRB
SCHEMBL422825 0.84 KDR (0.79) IKBKEKDRFLT3KITFLT1
SCHEMBL1379304 0.84 FLT3 (0.62) IKBKEKDRFLT3KITPDGFRB
SCHEMBL4739162 0.81 KDR (0.66) KDRFLT3KITPDGFRBFLT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2008080110-A1 METHODS FOR TREATING MACULAR EDEMA AND PATHOLOGIC OCULAR ANGIOGENESIS USING A NEUROPROTECTIVE AGENT AND A RECEPTOR TYROSINE KINASE INHIBITOR ALCON, INC. (CH) 2008-07-03 WO claimed
EP-1850839-A2 METHODS FOR TREATING OCULAR ANGIOGENESIS, RETINAL EDEMA, RETINAL ISCHEMIA, AND DIABETIC RETINOPATHY USING SELECTIVE RTK INHIBITORS ALCON INC. (CH) 2007-11-07 EP claimed
WO-2006091801-A2 METHODS FOR TREATING OCULAR ANGIOGENESIS, RETINAL EDEMA, RETINAL ISCHEMIA, AND DIABETIC RETINOPATHY USING SELECTIVE RTK INHIBITORS ALCON, INC. (CH) 2006-08-31 WO claimed
EP-1850839-A2 METHODS FOR TREATING OCULAR ANGIOGENESIS, RETINAL EDEMA, RETINAL ISCHEMIA, AND DIABETIC RETINOPATHY USING SELECTIVE RTK INHIBITORS ALCON INC. (CH) 2007-11-07 EP disclosed
WO-2006091801-A2 METHODS FOR TREATING OCULAR ANGIOGENESIS, RETINAL EDEMA, RETINAL ISCHEMIA, AND DIABETIC RETINOPATHY USING SELECTIVE RTK INHIBITORS ALCON, INC. (CH) 2006-08-31 WO disclosed